Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?

  • Maddalena Zippi | maddyzip@yahoo.it Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Roma, Italy.
  • Angeloluca De Quarto Unit of Oncology, Sandro Pertini Hospital, Roma, Italy.
  • Chiara Marzano Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Roma, Italy.
  • Claudio Cassieri Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Roma, Italy.
  • Pietro Crispino Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Roma, Italy.
  • Giampiero Traversa Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Roma, Italy.
  • Giuseppe Occhigrossi Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Roma, Italy.
  • Paola Gnerre Department of Internal Medicine, San Paolo Hospital, Savona, Italy.
  • David Terracina Unit of Internal Medicine, Sandro Pertini Hospital, Roma, Italy.

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with NSCLC present with advanced, metastatic disease at the time of diagnosis. For most patients with non-small cell lung cancer, current treatments do not cure the cancer. Therefore, there is a great need for development of more effective therapies. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) like erlotinib and gefitinib have been recognized as an important molecular target in cancer therapy and they are approved for the treatment of refractory advanced NSCLC patients. EGFR TKIs are generally well tolerated. The two most common toxicities include dermatologic and gastrointestinal side effects. Cases of gastrointestinal perforation, some of which were fatal, have also been reported in patients receiving erlotinib. Patients at increased risk include those taking concomitant anti-angiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs, and/or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease.

Downloads

Download data is not yet available.
Published
2016-08-11
Section
Case Reports
Keywords:
Epidermal growth factor receptor, tyrosine kinase inhibitors, erlotinib, gastrointestinal bleeding, non-small cell lung cancer, celecoxib.
Statistics
Abstract views: 1238

PDF: 487
HTML: 369
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Zippi, M., De Quarto, A., Marzano, C., Cassieri, C., Crispino, P., Traversa, G., Occhigrossi, G., Gnerre, P., & Terracina, D. (2016). Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?. Italian Journal of Medicine, 11(1), 75-77. https://doi.org/10.4081/itjm.2016.689

Most read articles by the same author(s)

1 2 > >>